Regulacje i polityka gospodarcza · 18/10/2001

National Institutes of Health to Consider Exclusive License for Thalidomide Analogs

The National Institutes of Health is seeking to grant an exclusive license to Celgene Corporation for its U.S. Patent Application 60/271,941, which explores the use of thalidomide analogs as potential angiogenesis inhibitors for treating oncology and inflammatory diseases.